Viatris Inc.
—- Market cap
- —
- Debt
- +$14.41B
- Cash
- −$1.32B
Complete market value, debt and cash evidence is required for enterprise value.
Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
Decision snapshot: VTRS stock price vs OCGN: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at OCGN's multiple
Needs OCGN P/S.
Implied fair value · at VTRS's multiple
Needs VTRS P/S.
Metric by metric
Where each company leads, and how wide the gap is.
Price unavailable
Growth lag
Pricing power
Operating leverage
Lower is better
Not comparable
Lower leverage
Statements
Core statements aligned to each company's latest fiscal year.
SEC periods: VTRS FY 2025 (ended Dec 31, 2025) · OCGN FY 2025 (ended Dec 31, 2025).
Trendline
Seven fiscal years of revenue, earnings, and margins before underwriting a re-rating.
Price framework
Market cap plus debt, less cash.
Complete market value, debt and cash evidence is required for enterprise value.
Complete market value, debt and cash evidence is required for enterprise value.
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
VIATRIS INC. · implied price per share
Debt and bridge-cash inputs are required to translate enterprise value into equity value.
OCUGEN, INC. · implied price per share
Latest annual free cash flow must be positive to qualify the filing-backed baseline.
Balance sheet health
Financial health checks to separate durable balance sheets from potential value traps.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Not enough data to score either balance sheet.
Debt / equity
Total debt against shareholders' equity
0.98x
-2.37x
Net debt / EBITDA
Leverage against operating earnings
561.72x
-0.16x
Cash and equivalents
Liquid reserves on the balance sheet
$1.32B
$18.57M
Total debt
Interest-bearing obligations outstanding
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
PFIZER INC
VTRS vs PFE
Organon & Co.
VTRS vs OGN
BRISTOL MYERS SQUIBB CO
VTRS vs BMY
AbbVie Inc.
VTRS vs ABBV
Merck & Co., Inc.
VTRS vs MRK
IOVANCE BIOTHERAPEUTICS, INC.
VTRS vs IOVA
bluebird bio, Inc.
VTRS vs BLUE
BioNTech SE
VTRS vs BNTX
Moderna, Inc.
VTRS vs MRNA
Legend Biotech Corp
VTRS vs LEGN
Arcturus Therapeutics Holdings Inc.
VTRS vs ARCT
$14.41B
$28.79M
LLM-powered synthesis
An explanation of the financial evidence. Check its snapshot date against the figures above.
The deterministic comparison remains available. Sign in when you want an on-demand narrative synthesis of the same data.